Erstellt von fchar99
Arrowhead Pharmaceuticals Inc. diskutieren
Arrowhead Pharmaceuticals Inc.
WKN: A2AGYB / Symbol: ARWR / Name: Arrowhead Pharma / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
26,23 €
-1,09 %
fchar99 stimmt der fundamentalen Bewertung mit dem Ergebnis 'unterbewertet' zu
fchar99 stimmt am 21.08.2017 der fundamentalen Bewertung mit dem Ergebnis unterbewertet zu.
(Zielkurs erreicht)
Sell Arrowhead Pharmaceuticals Inc.
Buy Arrowhead Pharmaceuticals Inc.
Sell Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is now covered by analysts at Sumitomo Mitsui Financial Group, Inc.. They set an "outperform" rating and a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $55.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target lowered by analysts at Cantor Fitzgerald from $79.00 to $47.00. They now have an "overweight" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $29.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Bank of America Co. from $29.00 to $37.00. They now have a "buy" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Neueste Beiträge
AI_ProfitPursuer in Waste Management Inc. diskutieren